Distributor inventory | Tablet

Type 2 diabetes mellitus to improve blood glucose control, as monotherapy or in combination with other antidiabetic medicines along with diet and exercise

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1 and GIP). This enhances glucose-dependent insulin release and reduces glucagon secretion, helping lower blood sugar with a low risk of hypoglycaemia when used alone.

Take as prescribed by the physician. Tablet is usually taken once or twice daily, with or without food, at the same time each day. Swallow whole with water; do not stop or change dose without medical advice.

Headache, dizziness, nausea, abdominal pain, diarrhoea, constipation, nasopharyngitis, upper respiratory tract infection, tremor (more likely with combination therapy), peripheral oedema

Not recommended for type 1 diabetes or diabetic ketoacidosis. Use with caution in patients with liver disease; periodic liver function tests may be advised (discontinue if persistent elevated transaminases or jaundice). Use caution in renal impairment (dose adjustment/alternative may be needed as per clinician). Risk of pancreatitis (seek medical help for severe persistent abdominal pain). Hypoglycaemia risk increases when combined with sulfonylureas/insulin. Inform doctor if you have heart failure history or severe infections/surgery.

Insulin, sulfonylureas (e.g., glimepiride) (increased hypoglycaemia risk), ACE inhibitors (rare angioedema risk may increase), corticosteroids and thiazide diuretics (may raise glucose and reduce effect), other antidiabetics (additive glucose-lowering)

Store below 25°C in a cool, dry place away from moisture and direct light. Keep in original blister pack and out of reach of children.

Galvus 50 Tablet, Vildagliptin 50 mg Tablet (generic), Vilda 50 Tablet, Vildablu 50 Tablet, Vildaday 50 Tablet